| 28.14 -2.495 (-8.14%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 35.05 |
1-year : | 39.66 |
| Resists | First : | 30.01 |
Second : | 33.95 |
| Pivot price | 29.7  |
|||
| Supports | First : | 23.62 |
Second : | 19.66 |
| MAs | MA(5) : | 31.03 |
MA(20) : | 29.36 |
| MA(100) : | 24.3 |
MA(250) : | 16.22 |
|
| MACD | MACD : | 1.1 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 62 |
D(3) : | 72.3 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 33.95 | Low : | 5.9 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SRZN ] has closed above bottom band by 33.0%. Bollinger Bands are 42.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 31.61 - 31.81 | 31.81 - 31.94 |
| Low: | 27.57 - 27.8 | 27.8 - 27.96 |
| Close: | 27.85 - 28.17 | 28.17 - 28.4 |
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Sat, 25 Apr 2026
How Surrozen Inc. (SRZN) Affects Rotational Strategy Timing - Stock Traders Daily
Thu, 23 Apr 2026
Point72 entities disclose 615,957-share (5.4%) holding in Surrozen (SRZN) - Stock Titan
Wed, 22 Apr 2026
Analysts’ Top Healthcare Picks: Surrozen (SRZN), Establishment Labs Holdings (ESTA) - The Globe and Mail
Tue, 21 Apr 2026
Surrozen, Inc. (NASDAQ:SRZN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Tue, 14 Apr 2026
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 5.42e+006 (%) |
| Held by Institutions | 3 (%) |
| Shares Short | 289 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.155e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 393.7 % |
| Return on Equity (ttm) | -35.8 % |
| Qtrly Rev. Growth | 3.48e+006 % |
| Gross Profit (p.s.) | -37.31 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.97885e+007 |
| Qtrly Earnings Growth | -32.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.77 |
| Dividend | 0 |
| Forward Dividend | 345450 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|